RECRUITING

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study aims to learn more about the impact the hormone aldosterone on the heart. Primary aldosteronism is a condition where the body's adrenal glands make too much of the hormone aldosterone, which can cause high blood pressure and increase the risk of heart and kidney disease. Treatment with medications that block aldosterone can reduce that risk. This study is trying to learn whether treatment with a medication that blocks aldosterone can improve heart function in people who make too much aldosterone.

Official Title

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Quick Facts

Study Start:2022-12-15
Study Completion:2027-02-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05030545

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults aged 18-85
  2. * Able to provide informed consent and willing to comply with the study
  3. * Able to fit safely in PET/CT scanner (weight limit 500 pounds; diameter and circumference of PET/CT scanner are 70 cm and 220 cm, respectively)
  4. * Hypertension treated with at least one antihypertensive drug
  5. * Cohort A: Clinically confirmed diagnosis of PA not yet treated with mineralocorticoid receptor antagonists
  1. * History of MI, CABG, known cardiomyopathy (EF \<40%, hypertrophic cardiomyopathy, and/or amyloid), cardiac transplantation
  2. * Contraindication or allergy to eplerenone or spironolactone
  3. * Current pregnancy or breastfeeding
  4. * eGFR \< 45 mL/min/1.73m2 or potassium \> 5.1 on labs within the preceding 3 months
  5. * Cohort A: Planned adrenalectomy in the subsequent 6 months

Contacts and Locations

Study Contact

Jenifer M Brown, MD
CONTACT
8573071990
jbrown35@bwh.harvard.edu

Study Locations (Sites)

Brigham and Women's Hospital
Boston, Massachusetts, 02115
United States

Collaborators and Investigators

Sponsor: Brigham and Women's Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-15
Study Completion Date2027-02-28

Study Record Updates

Study Start Date2022-12-15
Study Completion Date2027-02-28

Terms related to this study

Additional Relevant MeSH Terms

  • Primary Aldosteronism
  • Hypertension